A chimeric receptor of the insulin-like growth factor receptor type 1 (IGFR1) and a single chain antibody specific to myelin oligodendrocyte glycoprotein activates the IGF1R signalling cascade in CG4 oligodendrocyte progenitors

Biochimica et Biophysica Acta - Molecular Cell Research

Volumn 1813, Issue 8, 2011, Pages 1428-1437

  Annenkov, Alexander ^a   Rigby, Anne ^a   Amor, Sandra ^b   Zhou, Dun ^c   Yousaf, Nasim ^a   Hemmer, Bernhard ^c   Chernajovsky, Yuti ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Chimeric receptor; Gene therapy; Insulin like growth factor receptor type I; Oligodendrocyte progenitor; Receptor tyrosine kinase; Regenerative medicine

Indexed keywords

INSULIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN ANTIBODY; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR;

ANIMAL CELL; ARTICLE; CELL GROWTH; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; NEUROBLASTOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; RAT; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODY SPECIFICITY; CELL DIFFERENTIATION; CELL LINE; CELL SURVIVAL; HUMANS; INSULIN; MICE; MYELIN-ASSOCIATED GLYCOPROTEIN; NEURAL STEM CELLS; OLIGODENDROGLIA; PHOSPHORYLATION; PROTEIN SUBUNITS; RATS; RECEPTOR, IGF TYPE 1; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; SINGLE-CHAIN ANTIBODIES;

EID: 79959357256     PISSN: 01674889     EISSN: 18792596     Source Type: Journal    
DOI: 10.1016/j.bbamcr.2011.04.006     Document Type: Article

References (47)

1. Mason J.L., Ye P., Suzuki K., D'Ercole A.J., Matsushima G.K. Insulin-like growth factor-1 inhibits mature oligodendrocyte apoptosis during primary demyelination. J Neurosci 2000, 20:5703-5708.
2. Mason J.L., Jones J.J., Taniike M., Morell P., Suzuki K., Matsushima G.K. Mature oligodendrocyte apoptosis precedes IGF-1 production and oligodendrocyte progenitor accumulation and differentiation during demyelination/remyelination. J Neurosci Res 2000, 61:251-262.
3. Annenkov A. The insulin-like growth factor (IGF) receptor type 1 (IGF1R) as an essential component of the signalling network regulating neurogenesis. Mol Neurobiol 2009, 40:195-216.
4. Piddlesden S.J., Lassmann H., Zimprich F., Morgan B.P., Linington C. The demyelinating potential of antibodies to myelin oligodendrocyte glycoprotein is related to their ability to fix complement. Am J Pathol 1993, 143:555-564.
5. Johns T.G., Bernard C.C. The structure and function of myelin oligodendrocyte glycoprotein. J Neurochem 1999, 72:1-9.
6. Clements C.S., Reid H.H., Beddoe T., Tynan F.E., Perugini M.A., Johns T.G., Bernard C.C., Rossjohn J. The crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosis. Proc Natl Acad Sci USA 2003, 100:11059-11064.
7. Slavin A.J., Johns T.G., Orian J.M., Bernard C.C. Regulation of myelin oligodendrocyte glycoprotein in different species throughout development. Dev Neurosci 1997, 19:69-78.
8. Zhou D., Srivastava R., Nessler S., Grummel V., Sommer N., Bruck W., Hartung H.-P., Stadelmann C., Hemmer B. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci USA 2006, 103:19057-19062.
9. LeRoith D., Werner H., Beitner-Johnson D., Roberts C. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995, 16:143-163.
10. Ward C., Lawrence M., Streltsov V., Garrett T., McKern N., Lou M.Z., Lovrecz G., Adams T. Structural insights into ligand-induced activation of the insulin receptor. Acta Physiol Oxf 2008, 192:3-9.
11. Hubbard S.R., Mohammadi M., Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998, 273:11987-11990.
12. Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L., Stirdivant S.M., Darke P.L., Kuo L.C. Crystal structure of the Apo, unactivated insulin-like growth factor-1 receptor kinase. Implication for inhibitor specificity. J Biol Chem 2002, 277:38797-38802.
13. Liu D., Rutter W.J., Wang L.H. Enhancement of transforming potential of human insulin like growth factor 1 receptor by N-terminal truncation and fusion to avian sarcoma virus UR2 gag sequence. J Virol 1992, 66:374-385.
14. Liu D., Rutter W.J., Wang L.H. Modulating effects of the extracellular sequence of the human insulinlike growth factor I receptor on its transforming and tumorigenic potential. J Virol 1993, 67:9-18.
15. Li S., Zhang H., Hoff H., Sell C. Activation of the insulin-like growth factor type 1 receptor by deletion of amino acids 870-905. Exp Cell Res 1998, 243:326-333.
16. Takahashi K., Yonezawa K., Nishimoto I. Insulin-like growth factor I receptor activated by a transmembrane mutation. J Biol Chem 1995, 270:19041-19045.
17. Craddock B.P., Cotter C., Miller W.T. Autoinhibition of the insulin-like growth factor I receptor by the juxtamembrane region. FEBS Lett 2007, 581:3235-3240.
18. Schaffer L. A model for insulin binding to the insulin receptor. Eur J Biochem 1994, 221:1127-1132.
19. McKern N.M., Lawrence M.C., Streltsov V.A., Lou M.Z., Adams T.E., Lovrecz G.O., Elleman T.C., Richards K.M., Bentley J.D., Pilling P.A., Hoyne P.A., Cartledge K.A., Pham T.M., Lewis J.L., Sankovich S.E., Stoichevska V., Da Silva E., Robinson C.P., Frenkel M.J., Sparrow L.G., Fernley R.T., Epa V.C., Ward C.W. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006, 443:218-221.
20. Kalloo-Hosein H.E., Whitehead J.P., Soos M., Tavare J.M., Siddle K., O'Rahilly S. Differential signaling to glycogen synthesis by the intracellular domain of the insulin versus the insulin-like growth factor-1 receptor. Evidence from studies of TrkC-chimeras. J Biol Chem 1997, 272:24325-24332.
21. Baer K., Al-Hasani H., Parvaresch S., Corona T., Rufer A., Nolle V., Bergschneider E., Klein H.W. Dimerization-induced activation of soluble insulin/IGF-1 receptor kinases: an alternative mechanism of activation. Biochemistry Mosc 2001, 40:14268-14278.
22. Demaison C., Parsley K., Brouns G., Scherr M., Battmer K., Kinnon C., Grez M., Thrasher A.J. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002, 13:803-813.
23. Wissel K., Stover T., Hofmann N.S., Chernajovsky Y., Daly G., Sasse S., Warnecke A., Lenarz T., Gross G., Hoffmann A. Fibroblast-mediated delivery of GDNF induces neuronal-like outgrowth in PC12 cells. Otol Neurotol 2008, 29:475-481.
24. Chen C., Okayama H. High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol 1987, 7:2745-2752.
25. Naldini L., Blomer U., Gage F.H., Trono D., Verma I.M. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996, 93:11382-11388.
26. Naldini L., Blomer U., Gallay P., Ory D., Mulligan R., Gage F.H., Verma I.M., Trono D. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996, 272:263-267.
27. Yousaf N., Gould D.J., Aganna E., Hammond L., Mirakian R.M., Turner M.D., Hitman G.A., McDermott M.F., Chernajovsky Y. Tumor necrosis factor receptor I from patients with tumor necrosis factor receptor-associated periodic syndrome interacts with wild-type tumor necrosis factor receptor I and induces ligand-independent NF-ΚB activation. Arthritis Rheum 2005, 52:2906-2916.
28. Bottenstein J.E., Sato G.H. Growth of a rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci USA 1979, 76:514-517.
29. Louis J.C., Muir D., Varon S. Autocrine inhibition of mitotic activity in cultured oligodendrocyte-type-2 astrocyte (O-2A) precursor cells. Glia 1992, 6:30-38.
30. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
31. Ghattas I.R., Sanes J.R., Majors J.E. The encephalomyocarditis virus internal ribosome entry site allows efficient coexpression of two genes from a recombinant provirus in cultured cells and in embryos. Mol Cell Biol 1991, 11:5848-5859.
32. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 2001, 25:402-408.
33. Martinez-Salas E., Pacheco A., Serrano P., Fernandez N. New insights into internal ribosome entry site elements relevant for viral gene expression. J Gen Virol 2008, 89:611-626.
34. Stannard B., Blakesley V., Kato H., Roberts C.T., LeRoith D. Single tyrosine substitution in the insulin-like growth factor I receptor inhibits ligand-induced receptor autophosphorylation and internalization, but not mitogenesis. Endocrinology 1995, 136:4918-4924.
35. Favelyukis S., Till J.H., Hubbard S.R., Miller W.T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nat Struct Biol 2001, 8:1058-1063.
36. Recio-Pinto E., Ishii D.N. Insulin and insulinlike growth factor receptors regulating neurite formation in cultured human neuroblastoma cells. J Neurosci Res 1988, 19:312-320.
37. Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation. Structure 2001, 9:955-965.
38. Wu J., Li W., Craddock B.P., Foreman K.W., Mulvihill M.J., Ji Q.-s., Miller W.T., Hubbard S.R. Small-molecule inhibition and activation-loop trans-phosphorylation of the IGF1 receptor. EMBO J 2008, 27:1985-1994.
39. Belaus A., Merkle C., Fritsche M., Groner B. Crosstalk between the extracellular domain of the ErbB2 receptor and IGF-1 receptor signaling. J Steroid Biochem Mol Biol 2003, 85:105-115.
40. Jiang F., Frederick T.J., Wood T.L. IGF-I synergizes with FGF-2 to stimulate oligodendrocyte progenitor entry into the cell cycle. Dev Biol 2001, 232:414-423.
41. Frederick T.J., Wood T.L. IGF-I and FGF-2 coordinately enhance cyclin D1 and cyclin E-cdk2 association and activity to promote G1 progression in oligodendrocyte progenitor cells. Mol Cell Neurosci 2004, 25:480-492.
42. -/-) susceptible to oncogenic transformation. Exp Cell Res 2009, 315:1458-1467.
43. V integrins. Development 2000, 127:1961-1969.
44. Blakesley V.A., Koval A.P., Stannard B.S., Scrimgeour A., LeRoith D. Replacement of tyrosine 1251 in the carboxyl terminus of the insulin-like growth factor-I receptor disrupts the actin cytoskeleton and inhibits proliferation and anchorage-independent growth. J Biol Chem 1998, 273:18411-18422.
45. Esposito D.L., Blakesley V.A., Koval A.P., Scrimgeour A.G., LeRoith D. Tyrosine residues in the C-terminal domain of the insulin-like growth factor-I receptor mediate mitogenic and tumorigenic signals. Endocrinology 1997, 138:2979-2988.
46. Hongo A., D'Ambrosio C., Miura M., Morrione A., Baserga R. Mutational analysis of the mitogenic and transforming activities of the insulin-like growth factor I receptor. Oncogene 1996, 12:1231-1238.
47. O'Connor R., Kauffmann-Zeh A., Liu Y., Lehar S., Evan G.I., Baserga R., Blattler W.A. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 1997, 17:427-435.